Monday, 17 August 2015
SAINT PREX, Switzerland, 17 August 2015 – Ferring Pharmaceuticals announced initiation of patient enrollment in a phase 2b/3 clinical trial of selepressin for the treatment of septic shock, a life-threatening complication of infection affecting millions of people worldwide annually. The trial, SEPSIS-ACT, will be conducted at 50-60 sites in Europe and the United States and will enroll 1800 patients).
Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1
Canada
Tel: +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692
Ferring Pharmaceuticals is a research-driven biopharmaceutical company dedicated to researching, developing and marketing innovative treatments in a number of key therapeutic areas including reproductive health, urology, and gastroenterology. Founded in 1950, Ferring now operates from more than 55 countries and employs more than 4500 people throughout the world, while treatments are available in more than 100 countries. At its seven R&D centres, Ferring scientists strive to improve existing therapies and to create inventive new treatments that address unmet medical needs and help people of all ages live better. And, in every aspect of our business, we follow the Ferring Philosophy: “People Come First at Ferring”. It’s more than just five simple words. To us, it is a guiding principle that inspires everything we do - from our business practices to our relationships with patients and physicians.
Photo of Ferring Headquarters, Saint-Prex, Switzerland (www.ferring.com)
This Canadian website provides general information about Ferring Canada. For information about Ferring Global or its products in some other specific country, please go to ferring.com
FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise.
©2016 Ferring B.V.
